This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Third View: Discussing Verve Therapeutics' Phase1B results for VERVE-102, an in vivo base editing medicine targeting PCSK9.
Ticker(s): VERVWho's the expert?
- board-certified cardiologist with special interests in lipids management; complex coronary artery disease and peripheral vascular disease interventions; pacemaker implantation; and repair of structural heart defects.
Interview GoalThis conversation will focus on the treatment landscape and potential us of VERVE-102 for patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD).
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
